Poehling Capital Management INC. Sells 21,767 Shares of Pfizer Inc. $PFE

Poehling Capital Management INC. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 36.6% in the fourth quarter, Holdings Channel reports. The firm owned 37,672 shares of the biopharmaceutical company’s stock after selling 21,767 shares during the period. Poehling Capital Management INC.’s holdings in Pfizer were worth $938,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Horizon Financial Services LLC boosted its position in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the period. YANKCOM Partnership bought a new stake in Pfizer during the fourth quarter worth approximately $28,000. Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer in the third quarter valued at approximately $29,000. HFM Investment Advisors LLC boosted its position in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Darwin Wealth Management LLC bought a new stake in shares of Pfizer in the second quarter valued at approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a new Phase 3 endometrial cancer trial, signaling continued investment in its oncology pipeline and a potential long-term growth driver. Pfizer Takes Aim at Merck in New Phase 3 Endometrial Cancer Trial
• Positive Sentiment: Several recent opinion pieces argued that Pfizer still looks undervalued, which may be supporting bargain-hunting interest in the stock. Why Pfizer Stock Still Looks Deeply Undervalued In 2026
• Positive Sentiment: Technical commentary noted Pfizer’s RSI moved above 50, which traders often read as a sign of improving momentum. Tata Motors PV among 6 stocks showing bullish RSI upswing
• Neutral Sentiment: Analyst coverage remained unchanged at “Hold,” suggesting the market still sees Pfizer as fairly valued despite recent catalysts. Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of “Hold” from Analysts
• Negative Sentiment: Pfizer and other big drugmakers came under pressure after reports that the TrumpRx drug-pricing initiative may be set for “dramatic expansion,” reviving policy overhang concerns for the sector. PFE, NVO, LLY: Pharma Stocks Drop on News TrumpRx Set for ‘Dramatic Expansion’

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.66 on Wednesday. The business has a fifty day simple moving average of $26.93 and a 200 day simple moving average of $26.21. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $146.27 billion, a price-to-earnings ratio of 19.59 and a beta of 0.35. Pfizer Inc. has a one year low of $22.81 and a one year high of $28.75.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio is presently 131.30%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PFE. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. Bank of America reduced their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Guggenheim increased their price objective on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Citigroup increased their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Finally, Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $28.84.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.